-
MDA 2026: Dyne advances DMD therapy z-rostudirsen toward approval
Dyne Therapeutics is advancing its investigational exon-skipping therapy zeleciment rostudirsen (z-rostudirsen), formerly known as DYNE-251,
-
MDA 2026: This year’s MDA meeting provided a glimpse into the future
Muscular Dystrophy News Today is wrapping up coverage of the 2026 Muscular Dystrophy Association (MDA)








